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Muscle atrophy occurs under various catabolic conditions, including insulin deficiency, insulin resistance, or increased levels of
glucocorticoids. This results from reduced levels of insulin receptor substrate 1 (IRS-1), leading to decreased phosphatidylinosi-
tol 3-kinase activity and thereby activation of FoxO transcription factors. However, the precise mechanism of reduced IRS-1 un-
der a catabolic condition is unknown. Here, we report that C1-Ten is a novel protein tyrosine phosphatase (PTPase) of IRS-1 that
acts as a mediator to reduce IRS-1 under a catabolic condition, resulting in muscle atrophy. C1-Ten preferentially dephosphoryl-
ated Y612 of IRS-1, which accelerated IRS-1 degradation. These findings suggest a novel type of IRS-1 degradationmechanism
which is dependent on C1-Ten and extends our understanding of the molecular mechanism of muscle atrophy under catabolic
conditions. C1-Ten expression is increased by catabolic glucocorticoid and decreased by anabolic insulin. Reflecting these hor-
monal regulations, the muscle C1-Ten is upregulated in atrophy but downregulated in hypertrophy. This reveals a previously
unidentified role of C1-Ten as a relevant PTPase contributing to skeletal muscle atrophy.
Insulin receptor (IR) substrate 1 (IRS-1) is indispensable forpropagating insulin action from the IR to final cellular effects,
such as glucose uptake and protein synthesis (1, 2). Upon phos-
phorylation of tyrosine residues via an activated insulin receptor,
IRS-1 acts as a docking site for Src homology 2 (SH2) domain-
containing proteins such as phosphatidylinositol 3-kinase (PI3K),
Grb2, and SHP-2 (3). Reduced responsiveness to insulin typically
occurs at the level of IRS-1 (4), which, consequently, decreases the
IRS-1-associated PI3K/Akt pathway caused by a reduction of
IRS-1 tyrosine phosphorylation and the IRS-1 level itself (5–7).
Skeletal muscle accounts for75% of whole-body glucose up-
take and comprises 40% of body mass contributing to body
movement. Both glucose uptake and muscle mass are under the
control of IRS-1-associated PI3K activity. Therefore, defects in
IRS-1-associated PI3K activity in skeletal muscle contribute to
impaired glucose metabolism (8, 9) and loss of muscle mass,
known as muscle atrophy (10, 11).
Skeletal muscle atrophy occurs in patients with various cata-
bolic diseases, such as diabetes mellitus, sepsis, Cushing’s syn-
drome, and cancer (10–12). These conditions activate the ubiqui-
tin-proteasome pathway, which is associated with increased
expression ofmuscle RING finger 1 (MuRF1) andmuscle atrophy
F-box (MAFbx, also called atrogin-1). These E3 ligases are high-
fidelity markers of muscle atrophy not only in catabolic diseases
but also upon denervation or disuse (13–17). The Forkhead boxO
(FoxO) class of transcription factors is necessary for inducing
both MuRF1 and atrogin-1 (16). The transcriptional activity of
FoxOs is inhibited in growingmuscles by activation of the insulin-
like growth factor 1 (IGF-1)/PI3K/Akt pathway, which promotes
muscle hypertrophy (13, 18). During atrophy, the PI3K/Akt path-
way is inhibited by the reduced anabolic activity of insulin and
IGF-1 and by increased catabolic glucocorticoid, consequently ac-
tivating FoxOs (12, 18–20). Both in vivo and in vitro data have
demonstrated reduced levels of IRS-1 under atrophied conditions
(20–22), although themechanism of IRS-1 downregulation under
catabolic conditions is unclear.
C1-Ten (also known as tensin2) is a member of the tensin
family, which also includes tensin1, tensin3, and cten. All four
tensins contain C-terminal SH2 and PTB domains. tensin1, C1-
Ten, and tensin3 have a protein tyrosine phosphatase (PTPase)
domain, similar to PTEN (23). However, tensin1 lacks a cysteine
residue which is critical for any PTPase activity. In addition, C1-
Ten possesses a C1 domain. Recent papers suggested that only
C1-Ten, but not tensin3, has a PTEN-like activity in the cells (23,
24). However, there is no evidence that C1-Ten is a direct lipid
phosphatase like PTEN is. Additionally, the direct protein sub-
strate of C1-Ten remains unknown.
In this study, we demonstrated for the first time that C1-Ten is
a relevant PTPase of IRS-1. We also suggest a novel regulatory
mechanism for IRS-1 stability via IRS-1 Y612 dephosphorylation
by C1-Ten which explains the reduction of IRS-1 under catabolic
conditions. Furthermore, we found an inverse relationship be-
tween C1-Ten and IRS-1 levels in muscles undergoing atrophy.
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These results suggest the role of C1-Ten as a mediator of muscle
atrophy under a catabolic condition through degradation of IRS-1
via its PTPase activity.
MATERIALS AND METHODS
Antibodies and reagents. Anti-phospho-Akt (S473, T308), anti-phos-
pho-extracellular signal-regulated kinase (anti-phospho-ERK; T202/
Y204), anti-phospho-S6 kinase 1 (anti-phospho-S6K1; T389), anti-phos-
pho-IRS (S636/S639), anti-phospho-FoxO1/3a (T24/T32), anti-FoxO1,
anti-S6K1, and anti-ERK antibodies were purchased from Cell Signaling
(Danvers, MA). Anti-IRS-1 and anti-phospho-IRS-1 (Y612) were ob-
tained from Millipore (Darmstadt, Germany). Anti-Akt1/2, anti-myosin
heavy chain 1/2/3 (anti-MYH1/2/3), anti-PTEN, anti-phospho-IRS
(Y632, Y896), anti-py20, and anti-py99 were acquired from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti-laminin-2 was purchased from
Sigma-Aldrich (St. Louis, MO). Anti-myosin heavy chain (anti-MYH;
MF20) was acquired from Developmental Studies Hybridoma Bank
(Iowa City, IA). Anti-Tenc1 was obtained from Sigma and GeneTex Inc.
(Irvine, CA). Anti-Tenc1 from GeneTex was used at a 1:100 dilution for
studying C1-Ten in adult skeletal muscle because the anti-Tenc1 from
Sigma detected the highly abundantmuscle proteinMYH in adultmuscle.
IGF-1 (Long–R3–IGF-1), insulin, and dexamethasone (Dex) were pur-
chased from Sigma Chemical Co. (St. Louis, MO).
Cell culture. HEK293 cells and L6 myoblasts were grown and main-
tained in high-glucose Dulbecco’s modified Eagle’s medium (DMEM) or
low-glucose -minimal essential medium (-MEM) with 10% (vol/vol)
fetal bovine serum (FBS; Lonza). As the ability of myoblast fusion into
myotubes declines with passage, cells were used at low passages (6) for
all experiments. The medium was switched to -MEM with 2% (vol/vol)
FBS for differentiation and was replaced every 2 days. Atrophy experi-
ments were initiated on day 8, when myotubes were of constant size and
myotube fusion ceased.
Animals. All animal experiments were performed in our animal facil-
ity under POSTECH institutional guidelines. All animals, including
6-week-old male, obese, diabetic leptin receptor-deficient (db/db) mice
and lean littermate control (/ or /db) mice were maintained on a
12-h light–12-h dark cycle with regular unrestricted diets.
Plasmids. The full-length coding region of human C1-Ten (Tenc1
isoform 2, KIAA1075) cDNA (a gift fromKazusaDNAResearch Institute,
Chiba, Japan) was subcloned into the EcoRI/XbaI site of pFlag-CMV2
(Sigma) using the following primers: 5=-TAGAATTCATGAAGTCCAGC
GGCCCTGTGGAG-3= and 5=-GCTCTAGATCATTTTCTCTGGCCCA
GTAGAAC-3=. Flag–C1-Ten C231S was generated with a QuikChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA) using the follow-
ing primers: 5=-GTCGTACTATACTCCAAGGGAAACAAG-3= and 5=-C
TTGTTTCCCTTGGAGTATAGTACGAC-3=. The Flag–C1-Ten wild
type (WT) was subcloned into the EcoRI/SacII site of pEYFP-C1 (Clon-
tech, Palo Alto, CA) for the yellow fluorescent protein (YFP) constructs
using the following primers: 5=-TAGAATTCTATGAAGTCCAGCGGCC
CTGTGGAG-3= and 5=-TCCCCGCGGGGATCATTTTCTCTGGCCCA
GTAG-3=. The full-length coding region of human IRS-1 cDNA was
kindly provided by Michael J. Quon (University of Maryland, Baltimore,
MD). IRS-1 cDNA was subcloned into the EcoRI/XbaI site of pFlag-
CMV2 (Sigma) using the following primers: 5=-TAGAATTCAATGGCG
AGCCCTCCGGAGAGCGAT-3= and 5=-GCTCTAGACTACTGACGGT
CCTCTGGCTGCTT-3=. Flag–IRS-1 Y612F and Y632F were generated
with a QuikChange site-directed mutagenesis kit (Stratagene) using the
following primer pairs, respectively: primers 5=-ACGGATGATGGCTTC
ATGCCCATGTCCCCA-3= and 5=-TGGGGACATGGGCATGAAGCCA
TCATCCGT-3= and primers 5=-GGCAGTGGAGACTTTATGCCCATGA
GCCCC-3= and 5=-GGCAGTGGAGACTTTATGCCCATGAGCCCC-3=.
Purification of C1-Ten and in vitro PTPase assay. To purify the full-
length Flag–C1-Ten protein, three 10-cm dishes of HEK293 cells were
transfected with 3 g Flag–C1-Ten plasmids. After 48 h, the cells were
lysed in 1ml lysis buffer (50mMTris-HCl [pH 7.4], 150mMNaCl, 5mM
EDTA, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride [PMSF], 20
mM sodium fluoride [NaF], 0.025%mercaptoethanol, 1% Triton X-100,
0.2% sodium deoxycholate, a protease inhibitor mixture). The cell lysates
were sonicated and centrifuged at 14,000 rpm for 15 min at 4°C, and the
supernatant was incubated with 40 l of anti-Flag beads (Sigma) at 4°C
for 4 h. After the incubation, the beads were washed three times with lysis
buffer and once with wash buffer (50 mM Tris-HCl, 50 mM NaCl, 10%
glycerol, 5 mM dithiothreitol [DTT]). After the wash buffer was dis-
carded, the proteinwas elutedwith 80l elution buffer (50mMTris-HCl,
50 mM NaCl, 10% glycerol, 5 mM DTT, 100 g/ml Flag peptide) for 30
min, followed by a second elution with 40 l elution buffer for 30 min.
Approximately 8 ng/l C1-Ten was obtained. The PTPase activity of C1-
Tenwasmeasured once, immediately following purification, as its activity
quickly diminishes with time. A malachite green assay kit (17-125; Milli-
pore, Milford, MA) was used to determine the PTPase activity of C1-Ten
in vitro. A phosphate standard curve was generated for each experiment,
and enzyme reactions were performed in a final volume of 50 l reaction
buffer (50 mM Tris-HCl [pH 7.4], 50 mM NaCl, 5 mM DTT, 2 mM
MgCl2) in 96-well microtiter plates. The reaction was stopped by adding
120 l malachite green detection solutions. Color was developed for 15
min prior to measuring the absorbance of each well at 620 nm. Negative-
control wells contained enzyme only, and phosphate release was deter-
mined according to a standard curve. To prevent free phosphate contam-
ination from cell lysates, HEK293 cells expressing the Flag-CMV2 vector
were used and purification was performed in parallel with Flag–C1-Ten
WT and Flag–C1-Ten C231S (CS) purification. The following equation
was used to calculate PTPase activity: (pmol phosphate released from
Flag–C1-Ten WT or Flag–C1-Ten CS  pmol phosphate released from
Flag vector)/g enzyme. Glutathione S-transferase–PTEN was used as a
positive control.
Preparation of protein extracts. Crushed, snap-frozen tissues, and
harvested cells were lysed in buffer containing 50 mMTris-HCl (pH 7.4),
150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4, 20 mM NaF, 10 mM glyc-
erophosphate, 1 mM PMSF, 10% glycerol, 1% Triton X-100, 0.2% so-
dium deoxycholate, and protease inhibitor cocktail.
Recombinant Ads. Adenovirus (Ad)–C1-Ten WT and Ad–C1-Ten
CS were generated through homologous recombination between the lin-
earized pAd-Track-CMV vector carrying either Flag–C1-Ten WT or
Flag–C1-Ten CS and the adenoviral backbone vector pAd-Easy, as de-
scribed previously (25). Ad-green fluorescent protein (GFP) was used as a
control for all experiments with L6 myotubes. Viruses were purified with
an Adeno-Xmaxipurification kit (631532; Clontech) and titrated accord-
ing to the manufacturer’s instructions.
C1-Ten knockdown experiments. AllStars negative-control small in-
terfering RNA (siRNA) (con si) and C1-Ten siRNAs si1 (targeting the
C1-Ten sequence TCAGTGGATTACAACATGACA) and si2 (targeting
the C1-Ten sequence TCCAGTGGACACAGCACACTG) (Qiagen, Va-
lencia, CA, and Bioneer, Daejeon, South Korea) were introduced into
myotubes on day 6 of differentiation for hypertrophy experiments and on
day 8 of culture for dexamethasone-induced atrophy experiments using a
DeliverX Plus siRNA transfection kit (Panomics, Freemont, CA) accord-
ing to the manufacturer’s instructions.
In vivo transfection of adult skeletal muscle. Adult male mice
(weight, 30 g) were anesthetized, and the tibialis anteriormuscle of shaved
legs was injected with plasmids (25g in 30l sterile phosphate-buffered
saline [PBS]) along the muscle’s length. Then, 3 electric pulses were ap-
plied at 50 V/cm at 950-ms intervals with a square wave pulse electropo-
rator (BEX Co., Ltd., Japan).
Lentivirus transduction. 293T cells were transfected with plasmids
encoding control or C1-Ten short hairpin RNA (shRNA; sequence, GAG
GAAATTCTGTGAGGACAA) in pLKO.1 vectors (Sigma-Aldrich), vesic-
ular stomatitis virus glycoprotein, and delta 8.9 for 72 h.Media containing
lentiviruses were harvested and used for transduction of target cells for 24
h. Stable cell lines were selected in the presence of 3 g/ml puromycin
(Sigma-Aldrich).
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Quantitative real-time PCR (qRT-PCR) analysis. Total RNAwas ex-
tracted using the TRIzol reagent (Invitrogen, Carlsbad, CA), according to
the manufacturer’s protocol. Total RNA was reverse transcribed using an
ImProm-II reverse transcription system (Promega, Madison, WI), ac-
cording to the manufacturer’s instructions. The MyiQ real-time PCR de-
tection system (Bio-Rad, Hercules, CA) was used for detection and quan-
tification. The PCR was performed using SYBR Premix Ex Taq II DNA
polymerase (TaKaRaBio, Shiga, Japan). The PCRwas carried out in a final
volume of 20 l using 0.5 M each primer (listed below), cDNA, and 10
l of the supplied enzyme mixture containing the DNA double-strand-
specific SYBRgreen I dye for detecting PCRproducts. PCRwas performed
with a 3-min preincubation at 95°C, followed by 40 cycles of 15 s at 95°C
and 30 s at 60°C. PCRproducts were verified bymelting curve analysis and
agarose gel electrophoresis.
The sequences of the primers (intron-spanning primers) used were
as follows: for GAPDH (glyceraldehyde-3-phosphate dehydrogenase),
5=-CCATGACAACTTTGGCATTG-3= and 5=-CCTGCTTCACCACCTT
CTTG-3=; for C1-Ten, 5=-CTCAGTGGAGTTTGTTTTCTCCTC-3= and
5=-GCTGATTGAAGTTTTCATAGGAGTC-3=; for p85, 5=-GGCGATT
ACACTCTTACACTAAGGA-3= and 5=-GAGTTGAAGGTTAATGGATC
AGAGA-3=; for IRS-1, 5=-GTGAACCTCAGTCCCAACCATAAC-3= and
5=-CCGGCACCCTTGAGTGTCT-3=; and for MuRF1, 5=-AGTGTCCAT
GTCTGGAGGTCGTTT-3= and 5=-ACTGGAGCACTCCTGCTTGTAG
AT-3=.
Statistical analysis.Data are presented as means standard errors of
the means (SEMs). Comparisons between two groups were made by un-
paired two-tailed Student’s t tests. P values of 0.05 were considered
statistically significant.
RESULTS
C1-Ten is a candidate regulator ofmuscle function upregulated
in catabolic muscle. SH2 domain-containing proteins are crucial
for propagating signals from the receptor to final cellular effects,
and changes in the expression of many signaling molecules are
frequently observed in various diseases, including diabetes. Thus,
in an effort to identify novel proteins related to diabetes, we per-
formed qRT-PCR analysis of SH2 domain-containing proteins in
skeletal muscle fromwild-type and db/dbmice (see Fig. S1A in the
supplemental material). Our screening identified C1-Ten as a
potential protein that was significantly upregulated in diabetic
skeletal muscle (Fig. 1A), and the p85 subunit of PI3K was
used as a positive control (26, 27). To corroborate the observed
increase in C1-Ten mRNA, we determined the C1-Ten protein
level. Although commercially available C1-Ten antibodies did
not work well for detecting the abundance of endogenous pro-
teins corresponding to mRNA levels in tissues, a significant
increase in C1-Ten protein levels was observed in diabetic skel-
etal muscle (Fig. 1B).
To understand the functional meaning of the C1-Ten level in
muscle physiology, we firstmonitored C1-Ten expression in post-
natal development in vivo and myogenesis in vitro, during which
anabolic pathway is activated (28, 29). Interestingly, C1-Ten ex-
pression was high during the embryonic stage 17.5 and on post-
natal day 0 (P0) but decreasing on P21 (Fig. 1C), when significant
FIG 1 Expression of C1-Ten in catabolic and anabolic muscle. (A) C1-Ten and PI3K-p85 mRNA levels in the gastrocnemius muscles of db/db mice were
assessed by qRT-PCR and normalized to the gapdh level (n 5); (B) C1-Ten and p85 protein levels in the gastrocnemiusmuscles of db/dbmice (n 6); (C and
D) immunoblots showing C1-Ten expression during embryonic, postnatal development of skeletal muscle in mice (C) and L6 myogenesis (D). GM, growing
medium; DM, differentiation medium; E number, embryonic day; P numbers, postnatal days; M, male; F, female. S.E., short exposure; L.E., long exposure; *, P
 0.05; **, P 0.01; ***, P 0.001.
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myofiber hypertrophy begins (30). C1-Ten levels gradually de-
creased during myogenesis and were low on day 6 of differentia-
tion (Fig. 1D), in which fusedmyotubes typically increase in mass
(28, 29). Taken together, C1-Ten seems to be downregulated un-
der the anabolic condition. Thus, wemeasured theC1-Ten level in
the presence of catabolic glucocorticoid because glucocorticoid
increase has been reported in diabetic mice (31). Incubatingmyo-
tubes with synthetic glucocorticoid (i.e., Dex) caused the signifi-
cant increase of C1-Ten and the induction of MuRF1 E3 ligase, a
marker of muscle atrophy (see Fig. S1B in the supplemental ma-
terial). Next, we examined whether the C1-Ten increase occurred
under other catabolic conditions, like insulin deficiency. We in-
jected ratswith streptozotocin for 3 days, which induces acute type
1 diabetes. Under this insulin-deficient condition, we detected
increased levels of C1-Ten and MuRF1 (see Fig. S1C in the sup-
plemental material). In contrast to catabolic signals, anabolic in-
sulin treatment resulted in decreased C1-Ten levels (see Fig. S1D
in the supplemental material). Considering our findings that C1-
Ten levels decreased in terminally differentiated myotubes and
normal skeletal muscle but they were upregulated in catabolic
muscle, we suggest that C1-Ten might be associated with muscle
pathologies like muscle atrophy.
UpregulatedC1-Ten induces atrophy ofmyotubes under the
catabolic condition. Based on the decreased levels of C1-Ten in
anabolic muscle, we examined the effect of C1-Ten downregula-
tion on muscle function. Two distinct nonoverlapping siRNAs
against C1-Ten were tested. Both si1 and si2 reduced the basal
C1-Ten level, but si2 was more potent (Fig. 2A; see Fig. S2A in the
supplemental material). When the siRNA concentration was in-
creased to 100 nM, the knockdown efficiency of si1 on the C1-Ten
level was as effective as that of si2 (Fig. 2A). C1-Ten knockdown
produced thicker myotubes in the order of knockdown efficiency
(Fig. 2B). The mechanism of action seemed to involve the activa-
tion of anabolic pathways (i.e., Akt/S6K1) (Fig. 2A; see Fig. S2A in
the supplemental material). Thus, we asked whether C1-Ten de-
pletion is sufficient to reverse glucocorticoid-induced atrophy of
myotubes. We chose si1 for the restoration experiments to limit
the knockdown effects under the glucocorticoid-induced condi-
tion because si2 itself had a significant impact on myotube hyper-
trophy (Fig. 2B). This depletion of C1-Ten prevented glucocorti-
coid-induced atrophy (Fig. 2C) and blunted the induction of
MuRF1 (Fig. 2D).
Next, we examined whether C1-Ten expression is sufficient to
induce atrophy of myotubes. We used the adenovirus constructs
expressingGFP (see Fig. S2B in the supplementalmaterial), which
allowed us to visualize the morphology of construct-expressing
myotubes. Interestingly, C1-Ten overexpression for 60 h resulted
in a 40% reduction in mean myotube diameter compared to that
in cells expressing GFP (Fig. 2E). Mammalian cells contain three
members of the FoxO family, FoxO1, FoxO3, and FoxO4 (32).
Activation of FoxO1 and FoxO3 is sufficient to induce atrophy
(16, 18). C1-Ten overexpression resulted in the activation of FoxO
(reduction of FoxO1/3a phosphorylation) (Fig. 2F) and the sub-
sequent MuRF1 induction downstream of FoxO activation (Fig.
2G). In line with this, myosin heavy chain (MYH), a MuRF1 E3
ligase target (33), was also reduced in C1-Ten-expressing cells
(Fig. 2H), demonstrating that C1-Ten induces muscle atrophy by
activating the catabolic FoxO pathway. These results suggest that
increased C1-Ten induces muscle atrophy and that maintaining it
at a low level may be required for normal muscle function.
C1-Ten activates the catabolic pathway at the level of IRS-1.
Next, we wanted to know which step of the atrophy pathway is
modulated by C1-Ten. Reduced IRS-1 protein levels are observed
in various types of muscle atrophy (16, 18, 20). Under our condi-
tions, Dex treatment reduced the level of IRS-1 but not that of IR,
p85, or PTEN (see Fig. S2C in the supplemental material). Given
that Dex treatment caused IRS-1 reduction and C1-Ten knock-
down prevented Dex-induced muscle atrophy and activated Akt/
S6K1 pathways, we examined the effect of C1-Ten expression on
IRS-1 and signaling downstream of IRS-1 (Akt/S6K1 phosphory-
lation). In C1-Ten-expressing myotubes, the IRS-1 protein level
decreased significantly and a subsequent reduction in Akt/S6K1
phosphorylation was observed (Fig. 3A). However, no change in
IRS-1mRNA (Fig. 3B) or IR protein (Fig. 3A) levels was observed,
as in Dex-treated myotubes.
Because Dex caused the downregulation of IRS-1 and Akt/
S6K1 pathways and C1-Ten expression reduced IRS-1 levels and
inhibited the activation of Akt/S6K1, we tested whether the pre-
vention of Dex-induced atrophy by C1-Ten knockdown occurs
via restoration of the IRS-1 level. Depletion of Dex-induced C1-
Ten by si1 partially preserved the IRS-1 level and prevented the
subsequent decrease in Akt activation (Fig. 3C), suggesting that
C1-Ten induces muscle atrophy at the level of IRS-1 reduction.
Interestingly, si2 treatment, which was potent at reducing the
basal C1-Ten level, slightly reduced the basal IRS-1 level (see Fig.
S2A in the supplemental material). However, IRS-1 reduction by
Dex or si2 resulted in the opposite effects on signaling down-
stream of IRS-1 andmuscle size (Fig. 3D and 2C versus Fig. S2A in
the supplementalmaterial and Fig. 2A and B). Thus, we compared
the effect of IGF-1 or Dex on the IRS-1 level in myotubes. This is
based upon the finding that C1-Ten knockdown by si2 exerted
effects on Akt activation and hypertrophy of myotubes similar to
the effect of IGF-1 treatment (Fig. 2A and 3D; see Fig. S2A in the
supplemental material) and C1-Ten overexpression emulated the
effects of Dex treatment (Fig. 2E). Incubation of myotubes with
anabolic IGF-1 activated Akt signaling, but Dex treatment inhib-
ited Akt activation (Fig. 3D). In spite of this opposite action on
Akt, both hormones reduced the IRS-1 level (Fig. 3D), as in C1-
Ten si2-expressing or C1-Ten-overexpressing myotubes. Pro-
longed activation of Akt and S6K1 by IGF-1 is known to induce
IRS-1 reduction via negative feedback (34, 35), and a recent paper
showed that IGF-1 accelerated IRS-1 degradation in C2C12 myo-
tubes via a proteasome-dependent pathway (36). Thus, IRS-1 re-
duction by C1-Ten knockdown seemed to be caused by an S6K1-
dependent negative-feedback loop to restrain the anabolic effects
of IGF-1, as previously reported (36).
Next, we determined how C1-Ten overexpression affects the
IRS-1 level. Treatment with MG132, a proteasome inhibitor,
blocked the C1-Ten-induced reduction of IRS-1, indicating the
involvement of proteasomal degradation (Fig. 3E). C1-Ten-me-
diated IRS-1 reduction was independent of IRS-1 serine phos-
phorylation, demonstrated by IRS-1 serine phosphorylation (Fig.
3E) and treatment with inhibitors of PI3K and the mammalian
target of rapamycin (mTOR) (see Fig. S2E in the supplemental
material) in C1-Ten-expressing L6 myotubes. In C2C12 myo-
tubes, glucocorticoid was reported to reduce IRS-1 protein stabil-
ity, which is independent of S6K1 (37), as seen in our data. Taken
together, these results indicate that the C1-Ten-mediated IRS-1
reduction is mechanistically different from canonical insulin/
IGF-1-induced IRS-1 degradation.
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FIG 2 Muscle size regulations by C1-Ten expression or depletion. (A) (Top) Effect of C1-Ten depletion on S6K1 signaling. si1 (TCAGTGGATTACAACATG
ACA) and si2 (TCCAGTGGACACAGCACACTG) were used to deplete C1-Ten. Knockdown was done for 24 h on day 6 of differentiation. (Bottom) Levels of
C1-Ten protein relative to those of actin (n 3). con, control. (B) C1-Ten knockdownwas performed inmyotubes after 6 days of culture. Cells were fixed in 4%
paraformaldehyde in PBS for 20 min, washed twice with PBS, and permeabilized with 0.2% Triton X-100 for 5 min. After blocking with 3% bovine serum
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As we observed increased C1-Ten levels in skeletal muscle of
mice with acute type 1 or chronic type 2 diabetes (Fig. 1A and B;
see Fig. S1C in the supplementalmaterial) andmuscle atrophy has
been reported to be accelerated in these mice (10), we asked
whether the in vivo levels of IRS-1 decrease. Therewas a significant
reduction in the IRS-1 protein level (Fig. 3F).Next, we determined
whether FoxO activation occurs under our conditions. Although
phosphorylated FoxO1/3a levels were increased, total FoxO1 pro-
tein levels were increased to an even greater extent, resulting in a
reduction of the pFoxO1 and pFoxO3a/total FoxO1 ratio (Fig.
3F). Because dephosphorylated FoxOs can enter the nucleus and
turn on their target genes, FoxOs are activated in the skeletal mus-
cle of db/db mice. However, not only enhanced levels of cortisol
but also hyperinsulinemia are evident in thesemice (38), and both
of these can contribute to decreased IRS-1 levels in db/dbmice. In
insulin-deficient acute diabetes-induced muscle atrophy, we ob-
served amarked decrease in IRS-1 protein levels (Fig. 3G). This led
us to speculate that there must be a distinct IRS-1 degradation
mechanism possibly mediated by C1-Ten under a catabolic con-
dition. Taken together, the reduction in IRS-1 in muscle atrophy
in diabetes (i.e., acute type 1 or chronic type 2) can be due in part
to the reduced stability of IRS-1 as a result of increased C1-Ten
levels under catabolic conditions.
C1-Ten reduces IRS-1 stability via its PTPase activity. A re-
port has shown partial preservation of the reduction in IRS-1 lev-
els by maintaining tyrosine phosphorylation via an unidentified
mechanism (34). Incubating C1-Ten-expressing cells with vana-
date, a PTPase inhibitor, restored IRS-1 levels (see Fig. S2F in the
supplemental material), supporting the role of PTPase activity in
IRS-1 stability. Therefore, we asked whether C1-Ten is a PTPase
responsible for the C1-Ten-induced reduction in IRS-1. Even if
C1-Ten has the PTPase active-site signature motif, there is no
direct evidence for C1-Ten PTPase activity in vitro (23). There-
fore, we purified the full-length C1-Ten protein from HEK293
cells using a Flag immunoprecipitation/Flag peptide elution sys-
tem (Fig. 4A). This protein, together with phosphotyrosine-con-
taining peptides, demonstrated the time-dependent PTPase activ-
ity of C1-Ten (Fig. 4B). C1-Ten WT had activity comparable to
that of PTEN when the same amount of protein was used, but a
C1-Ten CS mutant in which catalytic residue cysteine 231 was
replaced by serine showed insignificant levels of PTPase activity
(Fig. 4C). Also, C1-Ten PTPase activity was abrogated by a general
PTPase inhibitor, vanadate, which suggests that C1-Ten is a rele-
vant PTPase (Fig. 4D).
In contrast to C1-Ten WT, C1-Ten CS activated signaling
downstreamof IRS-1 (i.e., Akt/S6K1) inmyotubes (see Fig. S2G in
the supplementalmaterial). There was also a reduction of IRS-1 in
C1-Ten CS-expressing myotubes, as in IGF-1-treated or C1-Ten
si2 expressing cells (Fig. 3D; see Fig. S2A and G in the supplemen-
talmaterial). As expected, treatment with rapamycin or LY294002
blocked C1-Ten CS-induced IRS-1 degradation, indicating that
this degradation is dependent on mTOR and PI3K activity (see
Fig. S2H in the supplemental material).
Due to the large accumulation of IRS-1 after just 2 h ofMG132
treatment, we hypothesized that the turnover rate of IRS-1 in
myotubes is fast. This might be because L6 cells produce approx-
imately 10 ng/ml IGF-2 (39). Therefore, we determined the effects
of C1-Ten on IRS-1 degradation after long-term treatment of
HEK293 cells with IGF-1 in order to trace C1-TenWT- or C1-Ten
CS-mediated IRS-1 reduction. Following 12 h of IGF-1 treatment,
IRS-1 protein was degraded in vector- or C1-Ten WT-expressing
cells, but C1-Ten CS blocked this degradation; however, it no
longer blocked IRS-1 degradation after 48 h of IGF-1 treatment
(see Fig. S2I in the supplemental material). Instead, there was
doublet of IRS-1 in C1-Ten CS-expressing cells because of the
mobility shift induced by hyperphosphorylation, which was most
evident under 10 nM IGF-1 treatment (see Fig. S2I in the supple-
mental material). Different from myotubes, preservation of ty-
rosine phosphorylation by C1-Ten CS blocked IRS-1 degradation
to some extent, which in turn led to prolonged activation of Akt
and mTOR, causing IRS-1 degradation, as seen in 3T3-L1 adi-
pocytes (34). This result in HEK293 cells helps our understanding
of the results seen in C1-Ten CS-expressing, C1-Ten si2-express-
ing, or IGF-treated myotubes. The differences in the role of ty-
rosine phosphorylation in IRS-1 stability between myotubes and
other cell types might be caused by the presence of cell type- or
tissue-specific E3 ligases targeting IRS-1 for degradation (36).
To clarify the role of C1-Ten PTPase activity on IRS-1 stability,
we monitored IRS-1 protein decay in the presence of the protein
synthesis inhibitor cycloheximide (CHX) for a subsequent 3-h
period inHEK293 cells. The rate of IRS-1 decaywas accelerated by
C1-Ten WT (Fig. 4E) but not by PTEN (Fig. 4F), supporting the
specificity of C1-Ten-induced IRS-1 reduction. IRS-1 decayed
more slowly in C1-Ten CS-expressing cells than in C1-Ten WT-
expressing cells (Fig. 4E), suggesting a role for tyrosine phosphor-
ylation on IRS-1 stability. Reflecting these IRS-1 level changes, Akt
phosphorylation was decreased by C1-TenWT but was sustained
by C1-Ten CS (Fig. 4E). Taken together, we propose that C1-Ten
regulates IRS-1 stability via its PTPase activity, which is the dis-
tinctive mechanism to reduced IRS-1 stability via anabolic path-
ways.
C1-Ten dephosphorylates Y612 of IRS-1, inducing IRS-1
degradation.Next, we checked the possibility that IRS-1 is a sub-
strate of C1-Ten. In general, the PTPase CS mutant traps its sub-
strate and forms a more stable complex with its substrate than the
WT PTPase. Immunoprecipitation experiments with IRS-1 after
albumin, cells were stained for themyosin heavy chain withMF20 antibody. Images were obtained with a confocal microscope (LSM-510Meta; Carl Zeiss, Jena,
Germany). Myotube diameter was measured in three spots along a 50-m length of a myotube. At 48 h after knockdown, the diameters of	50 myotubes were
measured and their mean diameters were calculated using ImageJ software. (C) Effect of C1-Ten depletion on atrophy induced by glucocorticoid. C1-Ten
knockdown was performed in myotubes after 8 days of culture. After 48 h, cells were stained with myosin heavy chain antibody. Images were obtained using a
confocal microscope (LSM-510Meta). The diameters of over 50 myotubes were measured. P values are compared to C1-Ten siRNA-treated (Dex-positive [Dex
]) cells. (D) The effect of C1-Ten knockdown on glucocorticoid-induced MuRF1 induction was determined by qRT-PCR. Data were normalized to gapdh
expression and are presented as the fold induction relative to dexamethasone-untreated [Dex ()] controls (n  3). (E) The diameter was determined by
infecting myotubes with GFP- or C1-Ten-expressing virus vectors. (Top) Images were taken 60 h after infection using a confocal microscope (LSM-510 Meta).
Bars, 100 m. (Bottom) More than 30 myotubes from independent experiments were measured. (F) (Left) Effect of C1-Ten on FoxO activation; (right)
quantification of pFoxO1 and pFoxO3a over FoxO1 (n 4). (G) Effect of C1-Ten onMuRF1 (n 6) expression. (H) Effect of C1-Ten onMYH levels (n 3).
*, P 0.05; **, P 0.01; ***, P 0.001.
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FIG 3 C1-Ten-induced muscle atrophy via IRS-1 reduction. (A) Effect of C1-Ten on Akt/S6K1 signaling and IRS-1 levels. (Left) Myotubes at 8 days of
differentiation were infected with Ad-GFP constructs for 48 h and subjected to immunoblotting; (right) levels of IRS-1 protein relative to those of Akt (n 5).
(B) The effect of C1-Ten on IRS-1 mRNA was determined by qRT-PCR (n  3). (C) (Left) Effect of C1-Ten knockdown on glucocorticoid-induced IRS-1
reduction inmyotubes. At 4 h posttransfection, myotubes were treated with 100 nM dexamethasone for 16 h. (Middle and right) protein levels presented as fold
induction relative to dexamethasone-untreated [Dex ()] sets (n 5). (D) To determine the effect of dexamethasone or IGF-1 on IRS-1 andAkt,myotubes were
infected with GFP- or C1-Ten-expressing virus vectors for 24 h and treated with 100 nMdexamethasone or 10 ng/ml IGF-1 for an additional 24 h. (E) The effects
of MG132 on C1-Ten-induced IRS-1 reduction were determined by treating L6 myotubes with 20 M MG132 for 2 h. (F) IRS-1 protein levels and FoxO
activation in gastrocnemius muscles of db/dbmice. IRS-1 and pFoxO1/3a protein levels were quantified relative to those of GAPDH (n 6) and FoxO1 (n 3),
respectively. (G) Protein level (left and middle) and mRNA level (right) of IRS-1 in gastrocnemius muscles of streptozotocin (STZ)-treated rats. Streptozotocin
(100 mg/kg of body weight) was dissolved in 0.1 M citrate buffer (pH 4.5) and injected into male rats (180 g) by the tail vein. Three days later, the rats were
anesthetized and muscle tissue was harvested (n 5). P values are compared to the control pair of fed rats. *, P 0.05; **, P 0.01; ***, P 0.001.
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insulin treatment demonstrated that C1-TenCS had amore stable
interaction with IRS-1 than C1-Ten WT (see Fig. S3A in the sup-
plemental material). To further validate that IRS-1 is a direct sub-
strate of C1-Ten, immunoprecipitation was performed in the ab-
sence or presence of vanadate, a phosphotyrosine mimetic. If the
interaction between the C1-Ten PTPase domain and IRS-1 is di-
rect, excess vanadate will compete with IRS-1 for binding to the
C1-Ten PTPase domain. In the presence of vanadate, less IRS-1
coimmunoprecipitated with C1-Ten (Fig. 5A), suggesting a direct
interaction between the two proteins. Reflecting the PTPase-sub-
strate relationship of C1-Ten and IRS-1, C1-Ten WT caused a
40% reduction in total IRS-1 tyrosine phosphorylation, whichwas
restored by C1-Ten CS (Fig. 5B), without affecting IR tyrosine
phosphorylation (see Fig. S3B in the supplemental material). C1-
Ten prevented Akt and ERK activation upon insulin stimulation
(Fig. 5C) and IGF-1 stimulation (see Fig. S3C in the supplemental
material), but it did not affect epidermal growth factor-mediated
Akt and ERK activation (see Fig. S3D in the supplemental mate-
rial), suggesting that C1-Ten specifically affects IRS-1-mediated
signaling.
IRS-1 contains 16 potential tyrosine sites (3); thus, we asked
whether C1-Ten could affect specific IRS-1 tyrosine residues. We
observed that C1-Ten significantly reduced the phosphorylation
of IRS-1 Y612 (human)/Y608 (mouse and rat) but not that of
IRS-1 Y632 or Y896 (Fig. 5D). C1-Ten-expressing myotubes also
had reduced IRS-1 Y608 (human Y612) phosphorylation com-
pared to GFP-expressing control cells after accumulating IRS-1
with MG132 (see Fig. S3E in the supplemental material). In con-
trast, C1-Ten shRNA-expressing myoblasts (see Fig. S3F in the
supplemental material) increased IRS-1 Y608 phosphorylation
(see Fig. S3G in the supplemental material). On Akt phosphory-
lation, IRS-1 Y612F showed effects (Fig. 5E) similar to those that it
showed in C1-Ten-expressing HEK293 cells (Fig. 5C; see Fig. S3C
in the supplemental material). Thus, these results indicate that
C1-Ten reduces IRS-1 tyrosine phosphorylation and preferen-
tially acts on IRS-1 Y612.
To determine whether IRS-1 Y612 dephosphorylation affects
IRS-1 stability, we monitored the rate of IRS-1 WT, Y612F, or
Y632F protein decay. IRS-1 Y612F decayed at a very high rate
during a subsequent 1-h period of CHX chasing compared to the
rate of decay of IRS-1 WT or IRS-1 Y632F (Fig. 5F). However,
incubation of IRS-1 Y612F-expressing cells with MG132 restored
the stability of IRS-1 Y612F to a level similar to that of IRS-1 WT
(Fig. 5G). Taken together, these results suggest that C1-Ten pref-
erentially dephosphorylates IRS-1 Y612, which induces protea-
some-mediated IRS-1 degradation.
C1-Ten causes atrophy of adult muscle fibers in a PTPase-
dependent manner. Because we observed that C1-Ten caused the
atrophy of myotubes through IRS-1 reduction via its PTPase ac-
tivity (Fig. 2C and E, 3A, and 4E) and C1-Ten levels increased in
atrophied muscle in vivo (Fig. 1A and B; see Fig. S1C in the sup-
plemental material), we asked whether C1-Ten affects muscle size
in vivo in its PTPase-dependent way. We transfected YFP-tagged
C1-Ten constructs (see Fig. S4A in the supplemental material)
FIG 4 Negative regulation of IRS-1 stability via C1-Ten PTPase activity. (A) Ponceau S staining revealed the quantity, integrity, and purity of the full-length
C1-Ten protein. (B) Time-dependent PTPase activity of C1-Ten. The malachite green assay was performed with 200 ng of C1-Ten and 400 M EEEEpYEEEE
peptide (n 3). (C) Cysteine-based PTPase activity of C1-Ten. C1-Ten CS and PTEN were used as the negative and positive controls, respectively. Error bars
indicate the SEMs of four independent experiments, each performed in triplicate. (D) Vanadate-mediated inhibition of C1-Ten PTPase activity. Error bars
indicate the SEMsof three independent experiments, each performed in duplicate. (E)CHXchase.HEK293 cells were transfectedwith vector (Vec), Flag–C1-Ten
WT, or Flag–C1-Ten CS. After 48 h, CHX (20 g/ml) and 10 nM insulin (Ins) were added and chased for the times indicated, followed by immunoblot analysis
(left) and graphical analysis (right). (F) HEK293 cells were transfected with vector or Flag-PTEN. After 48 h, CHX and insulin were added and chased, followed
by immunoblot analysis (left) and graphical analysis (right). *, P 0.05; **, P 0.01; ***, P 0.001.
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FIG 5 Accelerated degradation of Y612-dephosphorylated IRS-1. (A) IRS-1 as a substrate of C1-Ten. After HEK293 cells were treated with insulin for 5
min, immunoprecipitation (I.P.) was performed with anti-Flag antibody in the absence or presence of Na3VO4 and then subjected to immunoblotting
with anti-IRS-1 antibody. TCL, total cell lysate. (B) By using HEK293 cells, immunoprecipitation was performed with anti-IRS-1 antibody and the
immunoprecipitates were analyzed by immunoblotting with phosphotyrosine antibodies (py20  py99). (Top) Representative immunoblot; (bottom)
quantitation of pY-IRS-1 normalized to the amount for the insulin-stimulated vector (Vec) controls (n  3). (C) Effect of C1-Ten on the signaling
downstream of IRS-1 in HEK293 cells treated with insulin. HEK293 cells were transfected with vector or Flag–C1-Ten WT for 24 h. The cells were then
serum starved for 18 h prior to treatment with 50 nM insulin. (D) (Left) HEK293 cells were cotransfected with Flag–IRS-1 and YFP vector or YFP–C1-Ten
WT. After 48 h, immunoprecipitation was performed with anti-Flag antibody, and the immunoprecipitates were subjected to immunoblotting with
pY612, pY632, or pY896 antibodies of IRS-1. (Right)The amount of pIRS-1 was normalized to that of immunoprecipitated Flag–IRS-1 and represented
as the fold change over the result for the YFP vector (n  3). (E) Effect of IRS-1 YF mutants on insulin signaling. HEK293 cells were transfected with
Flag–IRS-1WT, Y612F, or Y632F. (F) Regulation of IRS-1 stability by IRS-1 Y612. CHX chase was used. Serum-starved HEK293 cells were incubated with
CHX for 1 h, followed by immunoblotting (top). The remaining amount of IRS-1 was normalized to the amount of Akt1/2 (bottom). (G) CHX and
MG132 were added to IRS-1 WT- or Y612F-expressing cells for 1 h. *, P  0.05; **, P  0.01; ***, P  0.001.
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into the tibialis anteriormuscles of mice via electroporation. As in
the cellular localization, C1-Ten formed cytoplasmic puncta in
adult skeletal muscle (40). We found that C1-Ten transfection
into muscles for 12 days resulted in a 25% reduction in mean
cross-sectional area (CSA) and a leftward shift in the distribution
of myofiber CSA (Fig. 6A). This was dependent on its PTPase
activity, as demonstrated by transfection with the C1-Ten CSmu-
tant. Taken together, these results propose that C1-Ten PTPase
can negatively regulate muscle function.
DISCUSSION
In this study, we newly identified C1-Ten to be a PTPase of IRS-1,
contributing to the degradation of IRS-1 and muscle atrophy un-
der catabolic conditions.
IRS-1 is a key mediator of the anabolic action of insulin/IGF-1
and regulates the balance between the anabolic and catabolic
pathways (1–4). Thus, a reduced level of IRS-1 has been regarded
as one of the key contributors for the development of catabolic
diseases, including diabetes (7, 11). Despite its importance, the
IRS-1 degradationmechanismunder catabolic status has not been
fully understood. The prevalent explanation for IRS-1 degrada-
tion is the PI3K- and mTOR-dependent pathway after long-term
insulin/IGF-1 stimulation (34, 35), which is one of the explana-
tions for IRS-1 reduction under conditions of hyperinsulinemia
(38). However, recent reports question the negative role of IRS-1
serine phosphorylation in insulin signaling because of conflicting
data from animal studies and cell-based experiments (41, 42).
Moreover, we and others have observed IRS-1 decreases under
catabolic states, such as glucocorticoid excess and insulin defi-
ciency, despite downregulation of the PI3K/mTOR pathway (20–
22, 37). This suggests the possibility that there is another mecha-
nism for IRS-1 degradation.
In this study, we showed for the first time that a novel IRS-1
degradationmechanismwhich is dependent onC1-Ten-mediated
tyrosine dephosphorylation of IRS-1 exists. We suggest that re-
duced tyrosine phosphorylation of IRS-1 contributes to IRS-1
degradation via a PI3K- and mTOR-independent pathway. More
specifically, we demonstrated that IRS-1 Y612, one of the most
important sites for PI3K activity, induced IRS-1 degradation upon
dephosphorylation by C1-Ten. However, it remains unclear how
Y612 of IRS-1, upon dephosphorylation, targets IRS-1 for degra-
dation. IRS-1 can be phosphorylated on tyrosine in both low-
density microsomes (LDM) and cytosol, but C1-Ten is localized
mainly in the cytosol, where the proteasomemachinery exists and
degradation occurs (40, 43, 44). Therefore, we assume that C1-
Ten dephosphorylates and degrades cytosolic IRS-1.However, the
dynamics of C1-Ten localization must be investigated to clarify
this issue. Even if C1-Ten preferentially reduced Y612 phosphor-
ylation of IRS-1 and the IRS-1 Y612F mutant showed similar im-
pacts on insulin signaling as C1-Ten WT did, there remain other
possibilities for the reduced IRS-1 stability conferred by C1-Ten.
It might be meaningful to determine the changes in interacting
partners or other phosphorylation sites of IRS-1 upon C1-Ten
overexpression. Another remaining issue is related to our finding
that the IRS-1 Y612F mutant itself exerted inhibitory effects on
insulin signaling and reduced its stability under the basal state.
This finding suggests that IRS-1 Y612 might be the most critical
residue contributing to catabolic disease. Even if IRS-1 Y612 ac-
counts for about 60% of PI3K activity (45), it needs to be deter-
mined whether this residue plays a key role in the progression of
catabolic diseases.
We have uncovered a novel role for C1-Ten as a catabolicmod-
ulator of skeletal muscle. Here, we showed that C1-Ten led to the
inhibition of an anabolic pathway (i.e., Akt/S6K1) and activation
of catabolic pathways (i.e., FoxO and MuRF1) via IRS-1 reduc-
tion. This seemed to cause a marked reduction in the diameter of
myotubes and, to a lesser extent, the CSA of adult myofibers. C1-
Ten-induced atrophy of myotubes and inhibition of signaling
downstream of IRS-1 in myotubes were fully restored by exoge-
nous insulin/IGF-1 incubation (Fig. 3D). In healthy animals, in-
sulin and IGF-1 are always present, and thismight compensate for
the C1-Ten overexpression effects in myofibers. Therefore, we do
not think that C1-Ten itself causes insulin resistance, despite its
ability to reduce IRS-1. This is also the case with IRS-1/mice, in
which a 50% reduction in the IRS-1 protein occurs. Even in dis-
ease states, there is no case of total deficiency of IRS-1. Thus,
studies using IRS-1/mice demonstrate that the IRS-1 reduction
itself is not sufficient to cause the development of overt insulin
resistance and diabetes. However, it is enough if there are other
minor defects in insulin signaling (46, 47). Thus, upregulation of
C1-Ten in combination with the catabolic condition, such as an
increase in glucocorticoids or insulin deficiency, exacerbates cat-
abolic states through IRS-1 reduction.
A recent study showed that inhibiting glucocorticoid hydrox-
ysteroid dehydrogenase type 1 (11 
-HSD1), producing active
cortisol, ameliorates the metabolic dysfunction in patients with
type 2 diabetes who failedmetforminmonotherapy (48).Our data
illustrate the hormonal regulation of C1-Ten expression by cata-
bolic (i.e., glucocorticoid) and anabolic (i.e., insulin) signals.
These findings suggest that C1-Ten reflects changes in hormonal
homeostasis and acts as an atrophymediator under catabolic con-
ditions. Considering this result, the development of a specific C1-
Ten inhibitor may be effective therapeutically to prevent muscle
atrophy in patients with catabolic diseases. Future studies that
genetically manipulate C1-Ten expression in animal models will
provide insights into the role ofC1-Tennot only in skeletalmuscle
but also in other tissues.
Our study contributes to data already published regarding the
physiological function of C1-Ten. Some studies suggest that C1-
Ten is a positive regulator of cell migration (49) and proliferation
by Akt activation (50), but other studies suggest that C1-Ten is a
negative regulator of cell migration and proliferation through in-
hibition of Akt (24). On the basis of our findings, the true effect of
C1-Ten on Akt activation may depend on the contribution of
IRS-1 and the basal state of cells, such as whether the IGF auto-
crine pathway is activated. In fact, we showed that C1-Ten expres-
sion in HEK293 cells inhibited insulin signaling via IRS-1 without
altering IRS-1 expression under a basal state. However, long-term
stimulation of C1-Ten-expressing HEK293 cells with insulin and
CHX showed a significant impact on the IRS-1 level. C1-Ten ex-
pression in L6 myotubes induced degradation of IRS-1 under the
basal condition, possibly because L6 cells produce approximately
10 ng/ml IGF-2 (39). C1-Ten activates Akt upon thrombopoietin
stimulation in megakaryocytic cells (50), which do not express
IRS-1 (51) but, rather, express IRS-2. However, C1-Ten may not
regulate IRS-2, as C1-Ten caused proteasomal degradation of
IRS-1 but increased IRS-2mRNA inmyotubes (see Fig. S2B in the
supplemental material), and short-term insulin stimulation fully
restored C1-Ten-dependent Akt inhibition in myotubes, possibly
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FIG 6 C1-Ten PTPase-dependent regulation on adult muscle size. (A) Adult tibialis anterior muscles were transfected with YFP-, YFP–C1-Ten WT-, or
YFP–C1-Ten CS mutant (C231S phosphatase-inactive mutant)-expressing vectors, and mice were killed after 12 days. Muscle cryosections (10 m thick) were
fixed with 4% paraformaldehyde at room temperature. After being rinsed with PBS, the cryosections were permeabilized with 0.2% Triton X-100 for 5 min and
blocked with 3% bovine serum albumin. Cryosections were stained for Hoechst and laminin. Images were obtained with a confocal microscope (Olympus,
Tokyo, Japan, or Leica sp5, Germany) andmergedwith the YFP signal. (Bottom left) Effect of C1-Ten expression onmean cross-sectional area (CSA).More than
	200 fibers expressing each YFP construct were measured (n 5). (Bottom right) Distribution of the CSA of fibers expressing YFP (control [Con]), YFP–C1-
TenWT (WT), or YFP–C1-Ten CS (CS). **, P 0.01. (B) Schematic depicting skeletal muscle atrophy induced by C1-Ten under pathological conditions. The
balance between anabolic and catabolic pathways is crucial for maintaining skeletal muscle mass. Anabolic pathways involving insulin and the IGF-1/IRS-1/Akt
pathway not only promote protein synthesis (hypertrophy) but also suppress catabolic pathways, represented by FoxOs/MuRF1, leading to protein degradation
(atrophy). Under pathological catabolic conditions, such as increased levels of glucocorticoids, insulin resistance, or insulin deficiency, C1-Ten is upregulated
and induces IRS-1 degradation through its PTPase activity, subsequently downregulating the anabolic pathway and leading to atrophy.
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due to an elevation in IRS-2 (Fig. 3D and E). This is consistent
with data for IRS-1/mouse embryonic fibroblasts and for skel-
etal muscle of IRS-1/mice (47, 52). A recent study using mus-
cle-specific IRS-1- or IRS-2-knockout mice suggested that IRS-1
has a more important role than IRS-2 in skeletal muscle with re-
spect tomusclemass and Akt signaling (53). However, both IRS-1
and IRS-2 are required for FoxO inhibition. Because IRS genes
were deleted in both skeletal muscle and cardiac muscle, these
mice showed sudden death at between 2 and 3 weeks of age be-
cause of cardiomyopathy. Therefore, the generation of inducible
conditional IRS-1-knockoutmicewill be required for detailed un-
derstanding of the IRS-1 function in the progression of muscle
atrophy.
Our study has identified a novel type of IRS-1 degradation
mechanism that explains the reduction in IRS-1 under catabolic
conditions and suggests that C1-Ten is a relevant IRS-1 PTPase
and a new therapeutic target for the treatment of muscle atrophy.
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